Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tregalizumab - Biotest

Drug Profile

Tregalizumab - Biotest

Alternative Names: Biotherapeutic agent BT-061 - Biotest AG; BT-061

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotest
  • Developer Biotest AG; T-Balance Therapeutics
  • Class Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma
  • Preclinical Graft-versus-host disease
  • Discontinued Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 28 Nov 2022 Preclinical trials in Graft-versus-host disease in Germany (Parenteral) (T-Balance Therapeutics pipeline, November 2022)
  • 28 Nov 2022 T-Balance Therapeutics plans a phase II clinical study in Graft-versus-host-disease (GvHD) (T-Balance Therapeutics pipeline, November 2022)
  • 25 Apr 2022 Biotest AG has been acquired by Grifols
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top